SpringWorks Therapeutics Reports Third Quarter 2022

– Presented Positive Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for...

Related Keywords

Germany ,Heidelberg ,Baden Wüberg ,Mannheim ,Bernd Kasper ,Malin Hultcrantz ,Saqib Islam ,Belantamab Mafodotin Belamaf ,Linkedin ,Nasdaq ,Development Rd Expenses ,Springworks Therapeutics Inc ,Mannheim Cancer Center ,European Society For Medical Oncology ,University Of Heidelberg ,Memorial Sloan Kettering Cancer Center ,Presented Positive Data ,Adult Patients ,Progressing Desmoid Tumors ,European Society ,Medical Oncology ,Expanded Global ,Non Exclusive Collaboration ,Continue Evaluating Nirogacestat ,Belantamab Mafodotin ,Multiple Myeloma ,Dosed First Patient ,Evaluating Nirogacestat ,Ovarian Granulosa Cell Tumors ,Strengthened Financial Position ,Cash Equivalents ,Marketable Securities ,Works Therapeutics ,Presidential Symposium ,Chief Executive Officer ,Business Highlights ,B Cell Maturation Antigen ,Beigene Sponsored Phase ,Carlos Alb ,Vice Chairman ,Chief Commercial Officer ,Loss Attributable ,Common Stockholders ,Nasdaq Swtx ,Springworks Therapeutics ,Nc ,